Recently, adiponectin has received renewed attention in oncology research as the data from several articles in the literature highlighted the link between the dysregulation of this adipokine and the risk of obesity-associated cancers, including breast, endometrial, lung and hematologic malignancies (i.e., leukemia, lymphoma and myeloma) [16,22]. Here, ADIPOQ is linked to cancer.